类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系

doi:10.11958/20230505

天津医药 ›› 2024, Vol. 52 ›› Issue (2): 193-196.doi: 10.11958/20230505

类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系

许文静(), 高冬梅, 李慧心, 王莉, 佟胜全^△()

唐山市工人医院风湿免疫科（邮编063000）

收稿日期:2023-04-20 修回日期:2023-07-18 出版日期:2024-02-15 发布日期:2024-01-26
通讯作者: ^△ E-mail：tonnymd@163.com
作者简介:许文静（1985），女，主治医师，主要从事风湿免疫方面研究。E-mail：295464176@qq.com
基金资助:
河北省医学科学研究课题(20231784)

Correlation analysis of serum Chemerin with disease activity and Th17/Treg in patients with rheumatoid arthritis

XU Wenjing(), GAO Dongmei, LI Huixin, WANG Li, TONG Shengquan^△()

Department of Rheumatology and Immunology, Tangshan Workers Hospital, Tangshan 063000, China

Received:2023-04-20 Revised:2023-07-18 Published:2024-02-15 Online:2024-01-26
Contact: ^△ E-mail: tonnymd@163.com

许文静, 高冬梅, 李慧心, 王莉, 佟胜全. 类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系[J]. 天津医药, 2024, 52(2): 193-196.

XU Wenjing, GAO Dongmei, LI Huixin, WANG Li, TONG Shengquan. Correlation analysis of serum Chemerin with disease activity and Th17/Treg in patients with rheumatoid arthritis[J]. Tianjin Medical Journal, 2024, 52(2): 193-196.

摘要/Abstract

摘要：

目的探究类风湿关节炎（RA）患者血清脂肪因子趋化素水平与疾病活动度和辅助性T细胞17/调节性T细胞（Th17/Treg）比值的相关性。方法纳入RA患者180例为观察组，根据DAS28评分将观察组分为高活动组、中活动组和低活动组，每组60例；另选取同期体检的健康者180例作为对照组。采用酶联免疫吸附试验（ELISA）法检测血清趋化素、白细胞介素（IL）-9、IL-10、IL-17水平；流式细胞术检测Th17/Treg比例；分析RA患者血清趋化素水平与DAS28评分，Th17、Treg细胞百分比及Th17/Treg比值的相关性。结果观察组血清趋化素水平高于对照组（P<0.05）。RA患者血清趋化素水平与DAS28评分呈正相关；高、中、低活动组血清趋化素水平和DAS28评分依次降低；观察组Th17细胞百分比、Th17/Treg比值、IL-17、IL-9水平高于对照组，Treg细胞百分比、IL-10水平低于对照组（P<0.05）。RA患者血清趋化素水平与Th17细胞百分比、Th17/Treg比值呈正相关，与Treg细胞百分比呈负相关（P<0.05）。结论 RA患者的血清趋化素水平升高，与疾病活动度和Th17/Treg比值具有密切关系。

关键词: 关节炎, 类风湿, 趋化因子类, Th17细胞, T淋巴细胞, 调节性, 白细胞介素类, 疾病活动度

Abstract:

Objective To explore the correlation of serum Chemerin level with disease activity and the ratio of T helper 17/regulatory T cells (Th17/Treg) in patients with rheumatoid arthritis (RA). Methods A total of 180 patients with RA who were admitted to our hospital were regarded as the observation group. According to the DAS28 score, the observation group was divided into the high activity group (60 cases), the moderate activity group (60 cases) and the low activity group (60 cases). Another 180 healthy people who underwent physical examination in our hospital during the same period were regarded as the control group. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of Chemerin, interleukin-9 (IL-9), interleukin-10 (IL-10) and interleukin-17 (IL-17). Flow cytometry was used to detect the Th17/Treg ratio. Spearman correlation analysis was applied to analyze the correlation between serum Chemerin level and DAS28 score. Pearson correlation analysis was used to analyze the correlation between serum Chemerin level and Th17, Treg cell percentage and Th17/Treg ratio. Results The results of this study showed that the serum level of Chemerin was higher in the observation group than that in the control group (P<0.05). The serum Chemerin level was positively correlated with DAS28 score (P<0.05). Serum Chemerin levels and DAS28 scores decreased in turn in the high, moderate and low activity groups (P<0.05). The percentage of Th17 cells and the ratio of Th17/Treg were higher in the observation group than those in the control group, and the percentage of Treg cells was lower in the observation group than that in the control group (P<0.05). The level of IL-10 was lower in the observation group than that in the control group, while levels of IL-17 and IL-9 were higher in the observation group than those in the control group (P<0.05). The results of Pearson correlation analysis showed that serum Chemerin level was positively correlated with the percentage of Th17 cells and the ratio of Th17/Treg, and negatively correlated with the percentage of Treg cells (P<0.05). Conclusion Serum Chemerin level is elevated in patients with RA, which is closely related to disease activity and Th17/Treg ratio.

Key words: arthritis, rheumatoid, chemotactic factors, Th17 cells, T-lymphocytes, regulatory, interleukins, disease activity

中图分类号:

R593.22

图/表 3

参考文献 19

[1]	LU S, ZHU M, GUO Q, et al. Metabolomic analysis of the urine from rats with collagen-induced arthritis with the effective part of caulophyllum robustum maxim[J]. Evid Based Complement Alternat Med, 2021, 2021:5580341. doi:10.1155/2021/5580341.
[2]	ZHU M, DING Q, LIN Z, et al. New targets and strategies for rheumatoid arthritis:from signal transduction to epigenetic aspect[J]. Biomolecules, 2023, 13(5):766. doi:10.3390/biom13050766.
[3]	WON W, CHOI H J, YOO J Y, et al. Inhibiting peripheral and central MAO-B ameliorates joint inflammation and cognitive impairment in rheumatoid arthritis[J]. Exp Mol Med, 2022, 54(8):1188-1200. doi:10.1038/s12276-022-00830-z.
[4]	刘梅娟, 王志刚. 类风湿关节炎不同中医证型与血清趋化素水平相关性研究[J]. 新中医, 2021, 53(8):41-46.
	LIU M J, WANG Z G. Discussion on relationship between level of chemerin in serum and Chinese medicine syndrome types in patients with rheumatoid arthritis[J]. Journal of New Chinese Medicine, 2021, 53(8):41-46. doi:10.13457/j.cnki.jncm.2021.08.011.
[5]	GONZALEZ-PONCE F, GAMEZ-NAVA J I, PEREZ-GUERRERO E E, et al. Serum chemerin levels:a potential biomarker of joint inflammation in women with rheumatoid arthritis[J]. PLoS One, 2021, 16(9):e0255854. doi:10.1371/journal.pone.0255854.
[6]	SHA S, ZENG H, GAO H, et al. Adherent-invasive Escherichia coli LF82 aggravated intestinal inflammation in colitis mice by affecting the gut microbiota and Th17/Treg cell differentiation balance[J]. Arch Microbiol, 2023, 205(6):218. doi:10.1007/s00203-023-03570-4.
[7]	任通, 朱芸, 桑雨婷, 等. D-二聚体、白介素-6、肿瘤坏死因子-α与类风湿关节炎活动性关系分析[J]. 中国现代医生, 2020, 58(4):1-4.
	REN T, ZHU Y, SANG Y T, et al. Analysis of activity relationship between D-dimer,interleukin-6,tumor necrosis factor-αand rheumatoid arthritis[J]. China Modern Doctor, 2020, 58(4):1-4.
[8]	中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4):242-251.
	Rheumatology Branch of Chinese Medical Association. 2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis[J]. Chinese Journal of Internal Medicine, 2018, 57(4):242-251. doi:10.3760/cma.j.issn.0578-1426.2018.04.004.
[9]	RZEPKA D, SCHENKER H, GEINITZ H, et al. Chromosomal radiosensitivity in oncological and non-oncological patients with rheumatoid arthritis and connective tissue diseases[J]. Radiat Oncol, 2023, 18(1):98. doi:10.1186/s13014-023-02291-8.
[10]	LIAO K P, SOLOMON D H. Lipids and cardiovascular risk through the lens of rheumatoid arthritis[J]. Arthritis & Rheumatology, 2019, 71(9):1393-1395. doi:10.1002/art.40891.
[11]	NII T, MAEDA Y, MOTOOKA D, et al. Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis[J]. Ann Rheum Dis, 2023, 82(5):621-629. doi:10.1136/ard-2022-222881.
[12]	苏显都, 林明利, 符步远, 等. 类风湿关节炎患者外周血单核细胞miR-24、miR-132表达及临床意义[J]. 中国免疫学杂志, 2020, 36(1):90-93.
	SU X D, LIN M L, FU B Y, et al. Expression and clinical significance of miR -24 and miR-132 in peripheral blood mononuclear cells of patients with rheumatoid arthritis[J]. Chinese Journal of Immunology, 2020, 36(1):90-93. doi:10.3969/j.issn.1000-484X.2020.01.017.
[13]	MACDONALD I J, LIU S C, HUANG C C, et al. Associations between adipokines in arthritic disease and implications for obesity[J]. Int J Mol Sci, 2019, 20(6):1505. doi:10.3390/ijms20061505.
[14]	NUGZAR O, ZANDMAN-GODDARD G, OZ H, et al. The role of ferritin and adiponectin as predictors of cartilage damage assessed by arthroscopy in patients with symptomatic knee osteoarthritis[J]. Best Pract Res Clin Rheumatol, 2018, 32(5):662-668. doi:10.1016/j.berh.2019.04.004.
[15]	张明萌, 张斌, 饶敏腊, 等. 肥胖相关的部分脂肪因子研究进展[J]. 中国医药, 2019, 14(6):952-956.
	ZHANG M M, ZHANG B, RAO M L, et al. Research progress of adipokines related with obesity[J]. China Medicine, 2019, 14(6):952-956. doi:10.3760/j.issn.1673-4777.2019.06.037.
[16]	李奇, 高晨曦, 芦恩婷, 等. 趋化素(Chemerin)对卵巢癌细胞的增殖、迁移及细胞周期的影响[J]. 解剖科学进展, 2020, 26(3):318-320,324.
	LI Q, GAO C X, LU E T, et al. The effect of chemerin on the proliferation, migration and cell cycle of ovarian cancer cells[J]. Progress of Anatomical Sciences, 2020, 26(3):318-320,324. doi:10.16695/j.cnki.1006-2947.2020.03.020.
[17]	姚血明, 马武开, 唐芳, 等. 类风湿关节炎患者DAS28积分与疾病活动指标的相关性分析[J]. 中国慢性病预防与控制, 2013, 21(1):79-81.
	YAO X M, MA W K, TANG F, et al. Correlation analysis between DAS28 score and disease activity indicators in patients with rheumatoid arthritis[J]. Chin J Prev Contr Chron Dis, 2013, 21(1):79-81. doi:10.16386/j.cjpccd.issn.1004-6194.2013.01.040.
[18]	张玉丽, 范锐, 隋华. 肠道微生态调控下的Th17/Treg细胞失衡及其在结直肠癌中的作用[J]. 现代肿瘤医学, 2022, 30(9):1684-1689.
	ZHENG Y L, FAN R, SUI H. The imbalance of Th17/Treg under the regulation of intestinal microecology and its role in colorectal cancer[J]. Modern Oncology, 2022, 30(9):1684-1689. doi:10.3969/j.issn.1672-4992.2022.09.033.
[19]	刘洁, 胡小辉, 龚道恺. 急性脑梗死患者外周血Th17、Treg、Th17/Treg及炎症因子的动态变化过程研究[J]. 临床神经病学杂志, 2020, 33(2):102-105.
	LIU J, HU X H, GONG D K. Dynamic variation of peripheral Th17,Treg,Th17/Treg and inflammatory biomarkers in patient with acute ischemic stroke[J]. J Clin Neurol, 2020, 33(2):102-105. doi:10.3969/j.issn.1004-1648.2020.02.006.

组别			CRP/（mg/L）		ESR/（mm/1 h）
对照组			1.56（0.76，2.98）		8.20（4.80，10.20）
观察组			20.50（4.10，64.00）		42.00（22.00，62.00）
Z			16.117^＊＊		9.937^＊＊
组别		类风湿因子/（IU/mL）				抗-CCP抗体/（U/mL）
对照组		18.00（13.50，24.20）				0.65（0.47，0.67）
观察组		102.00（18.00，486.00）				39.50（0.72，179.50）
Z		12.354^＊＊				23.289^＊＊
组别	补体C3/（g/L）			补体C4/（g/L）			趋化素/（μg/L）
对照组	1.05（0.92，1.21）			0.26（0.22，0.29）			50.48±15.96
观察组	1.14（0.97，1.27）			0.28（0.21，0.35）			75.69±24.25
Z或t	2.996			1.233			11.651^＊＊

组别			CRP/（mg/L）		ESR/（mm/1 h）
对照组			1.56（0.76，2.98）		8.20（4.80，10.20）
观察组			20.50（4.10，64.00）		42.00（22.00，62.00）
Z			16.117^＊＊		9.937^＊＊
组别		类风湿因子/（IU/mL）				抗-CCP抗体/（U/mL）
对照组		18.00（13.50，24.20）				0.65（0.47，0.67）
观察组		102.00（18.00，486.00）				39.50（0.72，179.50）
Z		12.354^＊＊				23.289^＊＊
组别	补体C3/（g/L）			补体C4/（g/L）			趋化素/（μg/L）
对照组	1.05（0.92，1.21）			0.26（0.22，0.29）			50.48±15.96
观察组	1.14（0.97，1.27）			0.28（0.21，0.35）			75.69±24.25
Z或t	2.996			1.233			11.651^＊＊

组别	趋化素/（μg/L）	DAS28/分
高活动组	88.40±24.56	7.89±1.72
中活动组	74.69±24.05^a	4.03±0.56^a
低活动组	63.98±24.14^ab	2.79±0.18^ab
F	15.286^＊＊	385.370^＊＊

组别	趋化素/（μg/L）	DAS28/分
高活动组	88.40±24.56	7.89±1.72
中活动组	74.69±24.05^a	4.03±0.56^a
低活动组	63.98±24.14^ab	2.79±0.18^ab
F	15.286^＊＊	385.370^＊＊

组别	Th17/%	Treg/%	Th17/Treg
对照组	0.56±0.18	4.23±1.28	0.13±0.05
观察组	1.65±0.39	3.48±0.72	0.47±0.14
t	34.046^＊＊	6.852^＊＊	30.684^＊＊
组别	IL-10/（ng/L）	IL-17/（ng/L）	IL-9/（ng/L）
对照组	27.32±3.79	5.96±0.65	6.09±0.68
观察组	17.56±3.14	13.74±2.28	13.25±2.09
t	26.605^＊＊	44.062^＊＊	43.707^＊＊

类风湿关节炎患者血清脂肪因子趋化素与疾病活动度和Th17/Treg的关系

Correlation analysis of serum Chemerin with disease activity and Th17/Treg in patients with rheumatoid arthritis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 3

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钟玉梅, 周海燕, 张敏. ASIC1a介导类风湿关节炎软骨细胞损伤机制的研究进展[J]. 天津医药, 2024, 52(9): 1004-1008.
[2]	袁满, 冯子瀚, 谢敏, 王柏军. 大黄素对骨关节炎模型小鼠痛觉行为的调节机制[J]. 天津医药, 2024, 52(6): 572-577.
[3]	罗锟, 王智, 王柯. 山姜素调节VEGF/SphK1/S1P信号通路对膝骨关节炎大鼠血管生成的影响[J]. 天津医药, 2024, 52(5): 480-485.
[4]	初吉燕, 田竞, 付笛语, 郭琳, 孙蕊, 李萍. AIM2炎症小体在急性痛风性关节炎中的表达及意义[J]. 天津医药, 2024, 52(5): 518-522.
[5]	王柯, 叶寒露. 隐丹参酮调节HIF-1α/BNIP3信号通路对兔膝骨关节炎模型软骨细胞自噬和凋亡的影响[J]. 天津医药, 2024, 52(4): 372-378.
[6]	乔坤艳, 刘韦娜, 郑晓雅, 苏瑞, 杨悦杰. 布鲁氏菌病患者外周血白细胞及血小板参数的变化及临床意义[J]. 天津医药, 2024, 52(4): 391-396.
[7]	王宁方, 赵崇山, 刘方, 赵鹏浩, 张东东, 蔡卓纹, 蔡芳芳. 多发性骨髓瘤患者淋巴细胞来源微泡的检测及其临床意义[J]. 天津医药, 2024, 52(4): 409-415.
[8]	邓雯雯, 孟祥虹, 孙振业, 杨奇龙, 王植. 膝内翻对膝骨关节炎股胫内外侧间室骨密度影响的QCT分析[J]. 天津医药, 2024, 52(12): 1291-1295.
[9]	李宏军, 钱亮, 邓新超, 余庭, 吴岩, 吴红丽. 舒筋活血胶囊通过JAK2/STAT3通路缓解大鼠膝骨关节炎的机制研究[J]. 天津医药, 2023, 51(9): 961-967.
[10]	覃达文, 杨秀程, 洪章萍, 熊倩妤, 蒙楠, 胡勇, 杨兴林. 贵州省HIV/AIDS患者合并梅毒感染病毒载量与T淋巴细胞亚群相关性分析[J]. 天津医药, 2023, 51(8): 851-854.
[11]	鲍布和, 张琪, 李海林, 杜双双, 高英堂. 血常规比值参数在类风湿关节炎中的诊断价值[J]. 天津医药, 2023, 51(11): 1271-1275.
[12]	王柯, 叶寒露. 大黄素对膝骨关节炎大鼠软骨细胞铁死亡的影响及机制研究[J]. 天津医药, 2023, 51(10): 1090-1097.
[13]	刘媛, 鲁芙爱, 王乐, 杨有国, 李小芬, 肖运平. lnc-NONHSAT074080调控靶基因ARL6IP4参与RA-UIP发病的机制研究[J]. 天津医药, 2023, 51(1): 1-7.
[14]	罗寰, 张霞, 冯娅娆, 赵悦, 任占芬, 杨金良, 郑学军. 托法替布与益赛普分别联合甲氨蝶呤治疗难治性类风湿关节炎的疗效及安全性分析[J]. 天津医药, 2022, 50(8): 883-887.
[15]	刘轩绮, 刘汇洋, 赵京洋, 尹芳蕊, 白力, 王永福, △. APC-EPCR-PAR1通路在类风湿关节炎中的研究进展[J]. 天津医药, 2022, 50(5): 552-556.